Semaglutide shortages are driving patients to compounding pharmacies. We need to help them verify whether this is a safe choice.
Professor, Department of Emergency Medicine, George Washington University, Washington, DC; Professor, Department of Emergency Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania; Chief of Clinical Innovation, US Acute Care Solutions, Canton, Ohio
The FDA went on to describe that many of the adverse events reported were consistent with known reactions in the labeling, like nausea,. Yet, they added that,"the FDA is unable to determine how, or if, other factors may have contributed to these adverse events, such as differences in ingredients and formulation between FDA-approved and compounded semaglutide products.
Ask whether the pharmacy is accredited by the Pharmacy Compounding Accreditation Board . Accreditation from the PCAB means that pharmacies have been assessed for processes related to continuous quality improvement. In addition, ask whether the pharmacy is designated as a 503B compounder and if not, why.
Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Drug Shortages Medication Shortages Toxicology Toxicity Poisoning Toxins Patient Safety GLP-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists Atherosclerotic Heart Disease Atherosclerotic Cardiovascular Disease Coronary Heart Disease Ischemic Heart Disease Coronary Artery Disease
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Texas patients turn to clinics for compounded semaglutide with Ozempic and WeGovy scarceAfter Ozempic and Wegovy burst onto the market in 2021 after gaining FDA approval for weight loss, 1 in 8 Americans have tried the pricey medications to cut...
Read more »
Semaglutide Kidney Benefits Extend to Those Without DiabetesThe effects in an obese population without diabetes and low rates of kidney disease suggest a 'potential role in the primary prevention of CKD.'
Read more »
Semaglutide Aids Weight Loss in Those With IBD and ObesitySemaglutide was equally effective for obesity in patients with or without IBD, with a more than 5% mean weight loss and no increased risk for disease-specific adverse events.
Read more »
Semaglutide Safe for Diabetics Before Surgery: StudyNew research showed patients taking the GLP-1 receptor agonist for diabetes were not at increased risk for postoperative pneumonia or other complications of surgery.
Read more »
Doctors Surprised When Patients Who Start Semaglutide Are Frequently Cured of Other ConditionsScience and Technology News and Videos
Read more »
SELECT: Semaglutide Reduces CV Events and Diabetes RiskTwo new analyses of the SELECT trial show that the GLP-1 receptor agonist improves cardiovascular health and reduces or normalizes glycemic levels irrespective of baseline A1c.
Read more »